Ron Ellis, co-founder of Endocyte, has led the biomedical company's success in securing $90M in capital to date. Located in Purdue Research Park, Endocyte has developed a novel technology to improve the safety and efficacy of potent drugs by targeting them directly to diseased cells in the treatment of cancer and other diseases.
Sponsored by: The Kauffman Foundation
In partnership with:
The Lilly Endowment Collegiate Entrepreneurship Opportunities Program
Hoosier Heartland Small Business Development Center
Discovery Learning and Research Center
